Gan & Lee Pharmaceuticals Co Ltd (603087) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gan & Lee Pharmaceuticals Co Ltd (603087) has a cash flow conversion efficiency ratio of 0.023x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥257.27 Million ≈ $37.65 Million USD) by net assets (CN¥11.28 Billion ≈ $1.65 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Gan & Lee Pharmaceuticals Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Gan & Lee Pharmaceuticals Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Gan & Lee Pharmaceuticals Co Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Gan & Lee Pharmaceuticals Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gan & Lee Pharmaceuticals Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Perseus Mining Ltd
AU:PRU
|
0.078x |
|
TAL Education Group
NYSE:TAL
|
-0.017x |
|
Randstad NV
AS:RAND
|
0.041x |
|
Ganfeng Lithium Co. Ltd
F:39EA
|
0.030x |
|
CCC Intelligent Solutions Holdings Inc. Common Stock
NASDAQ:CCCS
|
0.021x |
|
MGM China Holdings Limited
F:M04
|
0.939x |
|
SCOR SE
PA:SCR
|
0.091x |
|
One Gas Inc
NYSE:OGS
|
0.007x |
Annual Cash Flow Conversion Efficiency for Gan & Lee Pharmaceuticals Co Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of Gan & Lee Pharmaceuticals Co Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Gan & Lee Pharmaceuticals Co Ltd (603087) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥11.05 Billion ≈ $1.62 Billion |
CN¥537.31 Million ≈ $78.63 Million |
0.049x | +22.09% |
| 2023-12-31 | CN¥10.74 Billion ≈ $1.57 Billion |
CN¥427.69 Million ≈ $62.58 Million |
0.040x | +28.63% |
| 2022-12-31 | CN¥9.59 Billion ≈ $1.40 Billion |
CN¥296.68 Million ≈ $43.41 Million |
0.031x | -70.81% |
| 2021-12-31 | CN¥10.17 Billion ≈ $1.49 Billion |
CN¥1.08 Billion ≈ $157.77 Million |
0.106x | -23.64% |
| 2020-12-31 | CN¥8.94 Billion ≈ $1.31 Billion |
CN¥1.24 Billion ≈ $181.65 Million |
0.139x | -34.16% |
| 2019-12-31 | CN¥5.47 Billion ≈ $800.55 Million |
CN¥1.15 Billion ≈ $168.86 Million |
0.211x | +115.48% |
| 2018-12-31 | CN¥4.27 Billion ≈ $624.94 Million |
CN¥418.04 Million ≈ $61.17 Million |
0.098x | -65.62% |
| 2017-12-31 | CN¥3.34 Billion ≈ $488.07 Million |
CN¥949.60 Million ≈ $138.96 Million |
0.285x | -16.55% |
| 2016-12-31 | CN¥2.26 Billion ≈ $330.10 Million |
CN¥769.63 Million ≈ $112.62 Million |
0.341x | +13.29% |
| 2015-12-31 | CN¥1.49 Billion ≈ $217.41 Million |
CN¥447.42 Million ≈ $65.47 Million |
0.301x | +2.44% |
| 2014-12-31 | CN¥1.04 Billion ≈ $151.93 Million |
CN¥305.22 Million ≈ $44.66 Million |
0.294x | +5.28% |
| 2013-12-31 | CN¥733.22 Million ≈ $107.29 Million |
CN¥204.73 Million ≈ $29.96 Million |
0.279x | -- |
About Gan & Lee Pharmaceuticals Co Ltd
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin… Read more